Lucid Capital Markets Starts aTyr Pharma (ATYR) at Buy

Lucid Capital Markets analyst Dev Prasad initiates coverage on aTyr Pharma (NASDAQ: ATYR) with a Buy rating and a price target of $11.00.

The analyst comments "We are initiating coverage of aTyr Pharma (ATYR) with a Buy rating and an $11/share price target. aTyr is developing a pipeline of potential first-in-class therapies that target novel pathways regulated by extracellular tRNA synthetases. The company’s lead candidate, Efzofitimod, is in a Global Phase 3 EFZO-FIT trial for Pulmonary Sarcoidosis, where it has the potential to become the first FDA-approved therapy for the condition. Phase 1b/2a results demonstrated encouraging proof-of-concept, with dose-dependent reductions in steroid use and improvements in pulmonary function compared to placebo, positioning Efzofitimod as a moderately de-risked Phase 3 asset. Additionally, a proof-of-concept Ph1b/2a trial of Efzofitimod in SSc-ILD is ongoing. Efzofitimod’s mechanism of action and Ph1b/2a data in Pulmonary Sarcoidosis suggest it may have utility in a broader interstitial lung diseases (ILDs). Key upcoming potential catalysts, including proof-of-concept data in SSc-ILD (2Q25) and topline Ph3 data in Pulmonary Sarcoidosis (3Q25), could be inflection points for the stock."

For an analyst ratings summary and ratings history on aTyr Pharma click here. For more ratings news on aTyr Pharma click here.

Shares of aTyr Pharma closed at $3.01 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Aurora Spine settles patent dispute, secures $600K insider loan
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy